Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% – Should You Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares traded up 1.6% during mid-day trading on Friday . The stock traded as high as $30.52 and last traded at $29.82. 478,898 shares changed hands during trading, a decline of 9% from the average session volume of 526,191 shares. The stock had previously closed at $29.36.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Needham & Company LLC upped their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Canaccord Genuity Group upped their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Stock Up 1.6%

The company has a market cap of $1.86 billion, a PE ratio of -10.61 and a beta of 1.17. The stock’s 50 day simple moving average is $32.24 and its two-hundred day simple moving average is $32.36.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. Analysts forecast that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Jason Hoitt sold 1,931 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $60,517.54. Following the transaction, the insider owned 10,276 shares of the company’s stock, valued at $322,049.84. This trade represents a 15.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares in the company, valued at approximately $903,720.24. This represents a 13.83% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,291 shares of company stock worth $1,064,065. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares during the period. Goldman Sachs Group Inc. raised its stake in Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Jane Street Group LLC raised its stake in Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after purchasing an additional 15,001 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Stoke Therapeutics by 26.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock valued at $291,000 after acquiring an additional 5,398 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Stoke Therapeutics by 33.9% in the 2nd quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock valued at $754,000 after acquiring an additional 16,820 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.